Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154580 · ClinicalTrials.gov registry record · Phase 1
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
A Phase 1 study of Marijuana Abuse, sponsored by Wayne State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03154580: Completed Phase 1 study of Marijuana Abuse, sponsored by Wayne State University.
NCT03154580 is a Phase 1 study of Marijuana Abuse that has completed, run by Wayne State University. The registered enrollment target is 21 participants, below the 93-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154580, a Phase 1 study of Marijuana Abuse, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the proposed study is to examine the relationship between marijuana reminders, or "cues", craving for marijuana, and marijuana use. The principal investigator is also assessing whether N-acetylcysteine, can reduce marijuana craving or use.
Conditions Studied
Interventions
- DRUG N-acetyl cysteine
Study Locations (1)
Michigan
- Tolan Park Medical Building - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2023-06-27 |
| Phase | Phase 1 |
What the finished NCT03154580 record still lists
NCT03154580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 93-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Marijuana Abuse appearing as the primary indexed condition, and to 1 intervention - of which N-acetyl cysteine is the first listed.
NCT03154580 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03154580 about?
NCT03154580 is a clinical study titled "Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users". The purpose of the proposed study is to examine the relationship between marijuana reminders, or "cues", craving for marijuana, and marijuana use. The principal investigator is also assessing whether N-acetylcysteine, can reduce marijuana craving or use.
What is the current status of trial NCT03154580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-05-01. Estimated completion is 2023-06-27.
What conditions does trial NCT03154580 study?
This clinical trial studies the following conditions: Marijuana Abuse.
What interventions are being tested in trial NCT03154580?
The interventions under investigation include: N-acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT03154580?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03154580 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI